… Furthermore, the assessment of the role of systemic therapies in stages beyond advanced
stage HCC (early and intermediate stage) will be relevant to discover the full potential of …

… randomized trials addressed systemic therapy options in the second-line setting following
progression … No studies addressing systemic therapy options after lenvatinib or atezolizumab-…

… time to progression after previous sorafenib treatment and that the occurrence of AEs was
independent of the last sorafenib dose [31]. Multiple clinical trials are currently evaluating the …

… past decade, sorafenib has been the only systemic agent with proven clinical efficacy for
patients with unresectable hepatocellular carcinoma (HCC… ), and no prior systemic therapy, with …

… Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma
after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet …

… systemic treatments for hepatocellular carcinoma (HCC) has gained significant momentum in
recent years. After … and bevacizumab, as the first line treatment of advanced HCC, will bring …

… after surgical or loco-regional therapies 1 . In this section, we discuss the timings, selection
and prospects of systemic therapies for patients with HCC… stages and in first line at advanced …

… choice in the first line of patients with advanced HCC. … selection of first-line and subsequent
second-line systemic therapies, … Sorafenib or lenvatinib as preferred agents after first-line if …

… advanced treatment-naive patients with HCC. Therefore, systemic treatment for
advanced HCC currently … has significantly changed over the past few years. Atezolizumab/bevacizumab …

… to systemic therapies in advanced HCC and the lack of data on sequencing [Citation6]. …
shown controversial results as front-line treatment in advanced HCC. First, the CheckMate 040 …